Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | GNRHR | P30968 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 5/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882642 | 0.76 | HTR6 (0.68) | HTR6BRD4PRKCZCDK2HRH4 | |
| SCHEMBL4878647 | 0.72 | CXCR4 (0.44) | HTR6GNRHRPARP1HTR1AHTR1D | |
| SCHEMBL4889597 | 0.71 | HTR6 (0.60) | HTR6BRD4PRKCZCDK2 | |
| SCHEMBL4888363 | 0.70 | HTR6 (0.61) | HTR6BRD4PRKCZCDK2HRH4 | |
| SCHEMBL23122944 | 0.70 | HTR6 (0.58) | HTR6BRD4DRD2DRD3PRKCZ | |
| SCHEMBL21516099 | 0.68 | PARP1 (0.48) | HTR6BRD4PARP1 | |
| SCHEMBL10004541 | 0.68 | PARP1 (0.55) | HTR6BRD4PARP1HTR1A | |
| SCHEMBL1248548 | 0.67 | HTR1A (0.51) | HTR6BRD4DRD2DRD4DRD3 | |
| SCHEMBL5363679 | 0.65 | GNRHR (0.66) | HTR6DRD2DRD4DRD3GNRHR | |
| SCHEMBL7943360 | 0.64 | HRH4 (0.56) | HTR6PRKCZCDK2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1789045-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | HTR6 2334/4885BRD4 427/4885DRD2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.